Form 4: Revolution Medicines Exec Trades Shares

Revolution Medicines' Chief Financial Officer, Jack Anders, reported a series of stock transactions on June 24, 2026, including the acquisition of stock options and the sale of common stock.

Summary

• Jack Anders, Chief Financial Officer of Revolution Medicines, Inc., engaged in several stock transactions on June 24, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on March 24, 2026.
• Anders acquired 20,000 stock options at a price of $18.56 per share.
• He also sold a total of 20,000 shares of common stock through multiple transactions at weighted average prices ranging from $166.76 to $170.60.
• Following these transactions, Anders beneficially owns 123,269 shares of common stock, which includes 51,388 restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of stock by an executive can sometimes be perceived negatively, the execution under a 10b5-1 plan and the continued substantial ownership mitigate significant concern.

Positives

• The acquisition of 20,000 stock options indicates a potential for future equity participation and aligns management's interests with long-term company performance.
• The transactions were executed under a pre-established 10b5-1 trading plan, suggesting a structured and pre-determined approach to stock sales, which can mitigate concerns about insider trading.
• The reporting person retains a significant number of shares (123,269) and restricted stock units (51,388), indicating continued substantial beneficial ownership.

Negatives

• The sale of 20,000 shares of common stock by a key executive could be interpreted as a signal of reduced confidence in the short-term stock performance, although it was executed under a plan.
• The weighted average sale price across multiple transactions suggests a gradual divestment rather than a single large sale, but the total value of shares sold is substantial.

Risks

• The primary risk is the potential negative market perception of insider selling, even if conducted under a 10b5-1 plan, which could influence investor sentiment.
• The value of the acquired stock options is subject to future stock price performance and the vesting schedule, introducing performance-related risk for the executive.

Future Outlook

The filing does not contain forward-looking statements or guidance. The transactions are based on a pre-existing trading plan.

Management Comments

• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider stock transactions. The use of a 10b5-1 plan by Revolution Medicines' CFO is a common practice to facilitate planned stock sales while adhering to insider trading regulations. The specific prices and volume of shares traded will be closely watched by the market for any indications of management's sentiment towards the company's valuation.

Stakeholder Impact

• Shareholders: May interpret the stock sales as a negative signal, although the 10b5-1 plan provides a mitigating context. Continued substantial ownership by the CFO may offer some reassurance.
• Employees: Similar to shareholders, the perception of insider selling could influence morale, but the structured nature of the sale may lessen this impact.
• Management: The transactions reflect the CFO's personal financial planning and adherence to compliance regulations.

Next Steps

• The reporting person will continue to hold the acquired stock options and the remaining beneficial ownership of common stock.
• Future transactions, if any, will be subject to the terms of the 10b5-1 plan or new disclosures.

Key Dates

Keywords

Form 4, Insider Trading, Stock Options, Common Stock, 10b5-1 Plan, Beneficial Ownership, Revolution Medicines, RVMD, Executive Transactions, Securities Exchange Act